These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
262 related items for PubMed ID: 30655525
1. A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus. Flint M, Chatterjee P, Lin DL, McMullan LK, Shrivastava-Ranjan P, Bergeron É, Lo MK, Welch SR, Nichol ST, Tai AW, Spiropoulou CF. Nat Commun; 2019 Jan 17; 10(1):285. PubMed ID: 30655525 [Abstract] [Full Text] [Related]
9. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. Nature; 2011 Aug 24; 477(7364):344-8. PubMed ID: 21866101 [Abstract] [Full Text] [Related]
10. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Wang Y, Cui R, Li G, Gao Q, Yuan S, Altmeyer R, Zou G. Antiviral Res; 2016 Jan 24; 125():1-7. PubMed ID: 26585243 [Abstract] [Full Text] [Related]
11. Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications. Nelson EA, Barnes AB, Wiehle RD, Fontenot GK, Hoenen T, White JM. Viruses; 2016 Aug 02; 8(8):. PubMed ID: 27490565 [Abstract] [Full Text] [Related]
12. AAV8-mediated expression of N-acetylglucosamine-1-phosphate transferase attenuates bone loss in a mouse model of mucolipidosis II. Ko AR, Jin DK, Cho SY, Park SW, Przybylska M, Yew NS, Cheng SH, Kim JS, Kwak MJ, Kim SJ, Sohn YB. Mol Genet Metab; 2016 Apr 02; 117(4):447-55. PubMed ID: 26857995 [Abstract] [Full Text] [Related]
13. Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. Schafer A, Xiong R, Cooper L, Nowar R, Lee H, Li Y, Ramirez BE, Peet NP, Caffrey M, Thatcher GRJ, Saphire EO, Cheng H, Rong L. PLoS Pathog; 2021 Feb 02; 17(2):e1009312. PubMed ID: 33539432 [Abstract] [Full Text] [Related]
14. HER2-mediated enhancement of Ebola virus entry. Kuroda M, Halfmann P, Kawaoka Y. PLoS Pathog; 2020 Oct 02; 16(10):e1008900. PubMed ID: 33052961 [Abstract] [Full Text] [Related]
15. Inhibitors of signal peptide peptidase and subtilisin/kexin-isozyme 1 inhibit Ebola virus glycoprotein-driven cell entry by interfering with activity and cellular localization of endosomal cathepsins. Plegge T, Spiegel M, Krüger N, Nehlmeier I, Winkler M, González Hernández M, Pöhlmann S. PLoS One; 2019 Oct 02; 14(4):e0214968. PubMed ID: 30973897 [Abstract] [Full Text] [Related]
16. Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Sakurai Y, Kolokoltsov AA, Chen CC, Tidwell MW, Bauta WE, Klugbauer N, Grimm C, Wahl-Schott C, Biel M, Davey RA. Science; 2015 Feb 27; 347(6225):995-8. PubMed ID: 25722412 [Abstract] [Full Text] [Related]
17. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG. Sci Transl Med; 2013 Jun 19; 5(190):190ra79. PubMed ID: 23785035 [Abstract] [Full Text] [Related]
18. A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle. Martin S, Chiramel AI, Schmidt ML, Chen YC, Whitt N, Watt A, Dunham EC, Shifflett K, Traeger S, Leske A, Buehler E, Martellaro C, Brandt J, Wendt L, Müller A, Peitsch S, Best SM, Stech J, Finke S, Römer-Oberdörfer A, Groseth A, Feldmann H, Hoenen T. Genome Med; 2018 Aug 07; 10(1):58. PubMed ID: 30081931 [Abstract] [Full Text] [Related]
19. Growth-Adaptive Mutations in the Ebola Virus Makona Glycoprotein Alter Different Steps in the Virus Entry Pathway. Ruedas JB, Arnold CE, Palacios G, Connor JH. J Virol; 2018 Oct 01; 92(19):. PubMed ID: 30021890 [Abstract] [Full Text] [Related]